Abstract：
UNASSIGNED: To assess the effect of dienogest treatment on endometrioma (OMA) size, serum anti-Mullerian hormone (AMH) levels and associated pain over a 12-month follow-up period.
UNASSIGNED: A longitudinal cohort study of 104 patients with OMA who were treated with dienogest, between January 2017 and January 2020. Of the included patients, each had a 12-month follow-up period with transvaginal or pelvic ultrasound and measurement of serum AMH concentration at the sixth and twelfth months of follow-up. The alteration in OMA size in the sixth and twelfth months of treatment was the primary outcome measure and the alteration in AMH concentration over the same period was the secondary outcome measure. The only exclusion criterion was having surgical intervention for OMA during the follow-up period (n=44). In patients with bilateral OMA (n=21), the change in size of the largest OMA was considered in the analysis.
UNASSIGNED: A total of 60 patients with a mean ± standard deviation (SD) age of 31.5±8.0 years were included. The mean ± SD OMA size on the day the dienogest was started was 46.3±17.4 mm and the mean AMH level was 3.6±2.4 ng/mL. After six months, the mean OMA size had decreased to 38.6±14.0 mm, with a median difference of 7.8 mm [95% confidence interval (CI): 3.0 to 12.6; p=0.003]. The mean AMH level was 3.3±2.7 ng/mL at 6 months follow-up (95% CI: -0.2 to 0.8; p=0.23) and the average difference was 0.3 ng/mL. At the 12th-month visit, when compared with the beginning of the treatment, OMA size had again significantly decreased by a median of -8.9 mm (95% CI: -2.9 to -14.9; p=0.005), and the decline in median AMH was also significant (-0.9 ng/mL, 95% CI: -0.1 to -1.7; p=0.045). The initial mean ± SD visual analog scale pain score at the commencement of dienogest treatment was 6.3±3.4. The mean values at the sixth and twelfth months of dienogest therapy were 1.08±1.8 and 0.75±1.5, respectively (both p<0.001 compared to baseline).
UNASSIGNED: At the sixth and twelfth months of dienogest treatment a significant decrease in OMA size and reported pain scores were observed, whereas the AMH concentrations did not change significantly.
UNASSIGNED: A longitudinal cohort study of 104 patients with OMA who were treated with dienogest, between January 2017 and January 2020. Of the included patients, each had a 12-month follow-up period with transvaginal or pelvic ultrasound and measurement of serum AMH concentration at the sixth and twelfth months of follow-up. The alteration in OMA size in the sixth and twelfth months of treatment was the primary outcome measure and the alteration in AMH concentration over the same period was the secondary outcome measure. The only exclusion criterion was having surgical intervention for OMA during the follow-up period (n=44). In patients with bilateral OMA (n=21), the change in size of the largest OMA was considered in the analysis.
UNASSIGNED: A total of 60 patients with a mean ± standard deviation (SD) age of 31.5±8.0 years were included. The mean ± SD OMA size on the day the dienogest was started was 46.3±17.4 mm and the mean AMH level was 3.6±2.4 ng/mL. After six months, the mean OMA size had decreased to 38.6±14.0 mm, with a median difference of 7.8 mm [95% confidence interval (CI): 3.0 to 12.6; p=0.003]. The mean AMH level was 3.3±2.7 ng/mL at 6 months follow-up (95% CI: -0.2 to 0.8; p=0.23) and the average difference was 0.3 ng/mL. At the 12th-month visit, when compared with the beginning of the treatment, OMA size had again significantly decreased by a median of -8.9 mm (95% CI: -2.9 to -14.9; p=0.005), and the decline in median AMH was also significant (-0.9 ng/mL, 95% CI: -0.1 to -1.7; p=0.045). The initial mean ± SD visual analog scale pain score at the commencement of dienogest treatment was 6.3±3.4. The mean values at the sixth and twelfth months of dienogest therapy were 1.08±1.8 and 0.75±1.5, respectively (both p<0.001 compared to baseline).
UNASSIGNED: At the sixth and twelfth months of dienogest treatment a significant decrease in OMA size and reported pain scores were observed, whereas the AMH concentrations did not change significantly.
摘要：
■为了评估去甲治疗对子宫内膜瘤（OMA）大小的影响，12个月随访期间的血清抗苗勒管激素（AMH）水平和相关疼痛。
■一项对104例接受Dienogest治疗的OMA患者进行的纵向队列研究，2017年1月至2020年1月。在纳入的患者中，每个人都有12个月的随访期,在随访的第6个月和第12个月进行经阴道或盆腔超声检查,并测量血清AMH浓度.在治疗的第六个月和第十二个月中OMA大小的改变是主要结果指标，而在同一时期内AMH浓度的改变是次要结果指标。唯一的排除标准是在随访期间对OMA进行手术干预（n=44）。双侧OMA患者（n=21），分析中考虑了最大OMA大小的变化.
■共纳入60例患者，平均±标准差（SD）年龄为31.5±8.0岁。denogest开始当天的平均±SDOMA大小为46.3±17.4mm，平均AMH水平为3.6±2.4ng/mL。六个月后,平均OMA尺寸已降至38.6±14.0mm，中位数差异为7.8mm[95％置信区间（CI）：3.0至12.6；p=0.003]。随访6个月时，平均AMH水平为3.3±2.7ng/mL（95％CI：-0.2至0.8；p=0.23），平均差异为0.3ng/mL。在第12个月的访问中，与治疗开始时相比，OMA大小再次显着减少，中位数为-8.9mm（95％CI：-2.9至-14.9；p=0.005），AMH中位数的下降也很显著(-0.9ng/mL，95%CI：-0.1至-1.7；p=0.045）。开始治疗时的初始平均值±SD视觉模拟评分为6.3±3.4。在第6个月和第12个月治疗时的平均值分别为1.08±1.8和0.75±1.5(与基线相比均p<0.001)。
■在第6个月和第12个月治疗时，观察到OMA大小和报告的疼痛评分显着下降，而AMH浓度没有显著变化.
■一项对104例接受Dienogest治疗的OMA患者进行的纵向队列研究，2017年1月至2020年1月。在纳入的患者中，每个人都有12个月的随访期,在随访的第6个月和第12个月进行经阴道或盆腔超声检查,并测量血清AMH浓度.在治疗的第六个月和第十二个月中OMA大小的改变是主要结果指标，而在同一时期内AMH浓度的改变是次要结果指标。唯一的排除标准是在随访期间对OMA进行手术干预（n=44）。双侧OMA患者（n=21），分析中考虑了最大OMA大小的变化.
■共纳入60例患者，平均±标准差（SD）年龄为31.5±8.0岁。denogest开始当天的平均±SDOMA大小为46.3±17.4mm，平均AMH水平为3.6±2.4ng/mL。六个月后,平均OMA尺寸已降至38.6±14.0mm，中位数差异为7.8mm[95％置信区间（CI）：3.0至12.6；p=0.003]。随访6个月时，平均AMH水平为3.3±2.7ng/mL（95％CI：-0.2至0.8；p=0.23），平均差异为0.3ng/mL。在第12个月的访问中，与治疗开始时相比，OMA大小再次显着减少，中位数为-8.9mm（95％CI：-2.9至-14.9；p=0.005），AMH中位数的下降也很显著(-0.9ng/mL，95%CI：-0.1至-1.7；p=0.045）。开始治疗时的初始平均值±SD视觉模拟评分为6.3±3.4。在第6个月和第12个月治疗时的平均值分别为1.08±1.8和0.75±1.5(与基线相比均p<0.001)。
■在第6个月和第12个月治疗时，观察到OMA大小和报告的疼痛评分显着下降，而AMH浓度没有显著变化.
